Neoantigen Therapies Market Report 2026

Neoantigen Therapies Market Overview

• Neoantigen Therapies market size has reached to $0.96 billion in 2025 • Expected to grow to $2.83 billion in 2030 at a compound annual growth rate (CAGR) of 24.3% • Growth Driver: Rising Global Cancer Incidence Fueling The Growth Of The Market Due To Increasing Demand For Personalized And Targeted Cancer Immunotherapies • Market Trend: Advancements In Personalized Neoantigen Vaccine Development Accelerate Innovation In Cancer Immunotherapy • North America was the largest region and fastest growing region.

What Is Covered Under Neoantigen Therapies Market?

Neoantigen therapies are personalized cancer immunotherapies that target tumor-specific neoantigens formed by genetic mutations in cancer cells. These therapies utilize genomic sequencing, bioinformatics, and immune engineering technologies to activate precise immune responses against tumors with minimal impact on healthy tissues. Neoantigen therapies are designed to enhance treatment accuracy, strengthen anti-cancer activity, and advance personalized oncology care across various cancer indications. The main therapy types of neoantigen therapies include personalized neoantigen vaccines, off the shelf neoantigen therapies, adoptive T cell therapies, and other therapy types. Personalized neoantigen vaccines refer to patient-specific immunotherapies developed using unique tumor mutations to stimulate targeted anti-cancer immune responses. These therapies utilize technologies including next generation sequencing, bioinformatics, peptide synthesis, and other technologies and are administered through Intravenous, intradermal, and oral routes. They find application in lung cancer, melanoma, colorectal cancer, breast cancer, and others, serving end users including hospitals, cancer research institutes, specialty clinics, and others.

What Is The Neoantigen Therapies Market Growth Forecast?

The neoantigen therapies market size is expected to see exponential growth in the next few years. It will grow to $2.83 billion in 2030 at a compound annual growth rate (CAGR) of 24.3%. The growth in the forecast period can be attributed to expansion of AI-driven bioinformatics platforms for antigen prediction, increasing regulatory approvals for personalized cancer vaccines, rising investment in precision oncology research pipelines, development of scalable off-the-shelf neoantigen platforms, growing adoption of combination immunotherapy regimens in clinical oncology. Major trends in the forecast period include expansion of personalized neoantigen vaccine development using tumor-specific mutation profiling, increasing integration of AI-driven neoantigen prediction and epitope mapping for improved immunogenic accuracy, growth of mrna-based and peptide-based individualized cancer immunotherapies targeting patient-specific tumor signatures, rising adoption of next-generation sequencing guided precision oncology workflows for early tumor antigen identification, advancement in combination immunotherapy approaches integrating neoantigen therapies with checkpoint inhibitors for enhanced tumor suppression.

Global Neoantigen Therapies Market Segmentation

1) By Therapy Type: Personalized Neoantigen Vaccines, Off The Shelf Neoantigen Therapies, Adoptive T Cell Therapies, Other Therapy Types 2) By Technology: Next Generation Sequencing, Bioinformatics, Peptide Synthesis, Other Technologies 3) By Route Of Administration: Intravenous, Intradermal, Oral 4) By Application: Lung Cancer, Melanoma, Colorectal Cancer, Breast Cancer, Other Applications 5) By End User: Hospitals, Cancer Research Institutes, Specialty Clinics, Other End Users Subsegments: 1) By Personalized Neoantigen Vaccines: Peptide Based Neoantigen Vaccines, Ribonucleic Acid Based Neoantigen Vaccines, Deoxyribonucleic Acid Based Neoantigen Vaccines, Dendritic Cell Neoantigen Vaccines 2) By Off The Shelf Neoantigen Therapies: Shared Neoantigen Therapies, Pre Manufactured Cancer Vaccines, Allogeneic Neoantigen Therapies, Multi Target Neoantigen Platforms 3) By Adoptive T Cell Therapies: Tumor Infiltrating Lymphocyte Therapies, T Cell Receptor Engineered Therapies, Chimeric Antigen Receptor T Cell Therapies, Neoantigen Reactive T Cell Therapies 4) By Other Therapy Types: Combination Immunotherapies, Oncolytic Virus Based Neoantigen Therapies, Checkpoint Inhibitor Combination Therapies, Experimental Neoantigen Platforms

What Is The Driver Of The Neoantigen Therapies Market?

The rising global cancer incidence is expected to propel the growth of the neoantigen therapies market going forward. Cancer incidence refers to the number of new cancer cases diagnosed within a specific population during a certain period, reflecting the growing burden of cancer worldwide. The rise in global cancer incidence is primarily driven by the aging population, as cancer risk increases with age due to the accumulation of genetic mutations and prolonged exposure to environmental risk factors. Neoantigen therapies support cancer treatment by enabling highly personalized immunotherapies that target tumor-specific mutations, improving treatment precision and immune response effectiveness. For instance, in February 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, by 2050, over 35 million new cancer cases were projected, representing a 77% increase compared to the estimated 20 million cases in 2022. Therefore, the rising global cancer incidence is driving the growth of the neoantigen therapies industry.

Key Players In The Global Neoantigen Therapies Market

Major companies operating in the neoantigen therapies market are Moderna Inc., BioNTech SE, Agenus Inc., Immatics N.V., Elicio Therapeutics Inc., Nykode Therapeutics ASA, Creative Biolabs, Advaxis Inc., AIVITA Biomedical Inc., Medigene AG, Nouscom AG, Ultimovacs ASA, Geneos Therapeutics Inc., Treos Bio Limited, TVAX Biomedical Inc., Evaxion Biotech A/S, Circio Holding ASA, Transgene S.A., INTAVIS Peptide Services GmbH, Merck & Co., Bristol Myers Squibb, Roche/Genentech, AstraZeneca, GSK plc

Global Neoantigen Therapies Market Trends and Insights

Major companies operating in the neoantigen therapies market are focusing on advancing personalized cancer immunotherapy solutions, such as individualized neoantigen vaccines, to improve tumor-specific immune responses, enhance treatment precision, and support long-term disease control. Individualized neoantigen vaccines refer to customized immunotherapies developed using patient-specific tumor mutation profiles to stimulate targeted immune attacks against cancer cells. For instance, in April 2026, Transgene S.A., a France-based biotechnology company, announced the completion of randomization in its Phase II clinical trial evaluating TG4050, a personalized neoantigen therapeutic vaccine developed using its myvac platform. The therapy is designed to generate individualized immune responses against tumor-specific mutations in patients with head and neck cancer, supporting advancements in precision oncology and next-generation cancer immunotherapy development.

What Are Latest Mergers And Acquisitions In The Neoantigen Therapies Market?

In January 2026, BioNTech SE, a Germany-based biotechnology company focused on mRNA-based immunotherapies and cancer treatments, acquired CureVac N.V. for $1.25 billion. This acquisition strengthens BioNTech SE’s oncology and personalized cancer immunotherapy portfolio by expanding its capabilities in mRNA-based neoantigen therapies and individualized cancer vaccine development. CureVac N.V. is a Germany-based biotechnology company specializing in mRNA therapeutics, personalized cancer vaccines, and neoantigen-based immunotherapy platforms.

Regional Outlook

North America was the largest region in the neoantigen therapies market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Neoantigen Therapies Market?

The neoantigen therapies market consists of revenues earned by entities by providing services such as genomic profiling, neoantigen identification, personalized vaccine development, immune cell engineering, clinical trial support, and precision oncology treatment solutions. The market value includes the value of related goods sold by the service provider or included within the service offering. The neoantigen therapies market also includes sales of neoantigen peptide vaccines, neoantigen mrna therapeutics, dendritic cell-based immunotherapies, and neoantigen-targeted combination immunotherapies. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Neoantigen Therapies Market Report 2026?

The neoantigen therapies market research report is one of a series of new reports from The Business Research Company that provides neoantigen therapies market statistics, including neoantigen therapies industry global market size, regional shares, competitors with a neoantigen therapies market share, detailed neoantigen therapies market segments, market trends and opportunities, and any further data you may need to thrive in the neoantigen therapies industry. This neoantigen therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.